TD Cowen analyst Tara Bancroft raised the firm’s price target on Protagonist Therapeutics (PTGX) to $100 from $90 and keeps a Buy rating on the shares. The firm said Protagonist is well positioned with two potential launches in H2, rusfertide and Ico. An opt-out decision for rusfertide is expected in Q2, enabling a meaningful revenue stream.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics: Near-Term Cash Windfall and Strategic Partnerships Underpin Buy-Rated, Self-Funded Growth Story
- Protagonist Therapeutics price target raised to $112 from $102 at Citizens
- Protagonist Therapeutics price target raised to $113 from $108 at Barclays
- Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target
- Protagonist Therapeutics price target raised to $117 from $80 at H.C. Wainwright